Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

44.93USD
26 Nov 2014
Price Change (% chg)

$0.26 (+0.58%)
Prev Close
$44.67
Open
$44.67
Day's High
$45.00
Day's Low
$44.64
Volume
142,534
Avg. Vol
204,518
52-wk High
$49.10
52-wk Low
$34.30

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 0.93
Market Cap (Mil.): $94,165.77
Shares Outstanding (Mil.): 2,112.56
Dividend: 0.83
Yield (%): 1.86

Financials

  NVO.N Industry Sector
P/E (TTM): 27.33 38.09 39.03
EPS (TTM): 1.63 -- --
ROI: 65.79 17.96 17.31
ROE: 71.98 18.76 18.22
Search Stocks

NORDIC STOCKS - Factors to watch on Nov 25

OSLO, Nov 25 - The following stocks may be affected by newspaper reports and other factors on Tuesday:

25 Nov 2014

BRIEF-Novo Nordisk has reduced the number of executives to six

COPENHAGEN, Nov 25 - Novo Nordisk A/S : ** Has reduced the number of executives from seven to six ** Executive vice president and chief of staffs Lise Kingo has decided to leave Novo Nordisk

25 Nov 2014

BRIEF-Novo'S victoza receives positive opinion for use in adults with type 2 diabetes

COPENHAGEN, Nov 21 - Novo Nordisk A/S : ** Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment ** Once the European Commission approves the label expansion, physician s in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments

21 Nov 2014

BRIEF-Nine out of 10 lost weight with Novo's obesity drug -study

Nov 4 - Novo Nordisk A/S says: * New phase 3a data demonstrate that nine out of 10 adults with obesity lost

04 Nov 2014

BRIEF-Novo Nordisk invests $130 mln in diabetes research in Denmark

* Invests 750 million Danish crowns in new laboratories for diabetes research in Denmark (around $130 million)

31 Oct 2014

Novo Nordisk reassures on 2015 outlook after Sanofi jolt

COPENHAGEN - Novo Nordisk reassured investors that its diabetes drugs business in the United States would continue to grow, after French rival Sanofi warned that price competition would hamper its U.S. sales.

30 Oct 2014

UPDATE 3-Novo Nordisk reassures on 2015 outlook after Sanofi jolt

* Shares up almost 4 percent (Adds analysts, details on Tresiba, updates shares)

30 Oct 2014

Novo Nordisk more cautious on timing of U.S. Tresiba launch

COPENHAGEN - Novo Nordisk is more cautious in its assessment of when it would launch its Tresiba diabetes drug in the United States, a critical growth driver for the future, according to statements it made in its quarterly report.

30 Oct 2014

Novo Nordisk more cautious on timing of U.S. Tresiba launch

COPENHAGEN, Oct 30 - Novo Nordisk is more cautious in its assessment of when it would launch its Tresiba diabetes drug in the United States, a critical growth driver for the future, according to statements it made in its quarterly report.

30 Oct 2014

Novo Nordisk says will update on possible NNIT IPO in Jan

COPENHAGEN - Denmark's Novo Nordisk said on Thursday that it would provide an update on whether or not to list its IT subsidiary NNIT on January 30, when it provides its next earnings report.

30 Oct 2014

Competitors

  Price Change
Sanofi SA (SASY.PA) €76.43 --
Eli Lilly and Co (LLY.N) $67.32 +0.47

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks